Swiss big pharmas top the research spending tables
Over the past decade Roche and Novartis consistently spent more on R&D than other big pharma groups, while Abbvie and Astrazeneca have added to their budgets.
Are all new sales created equal?
Pipeline projects are forecast to contribute a substantial proportion of future sales at Abbvie and Lilly, though the same cannot be said for all big drug developers.
Axovant looks to Oxford Biomedica for gene therapy resurrection
Axovant transforms itself into a new gene therapy company with an old Oxford Biomedica product.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.